Blog
RSS FeedPosted by Michael Wonder on 29 May 2023
A review of HTA guidelines on societal and novel value elements
25 May 2023 - Health technology assessment organisations vary in terms of how they conduct assessments. ...
Posted by Michael Wonder on 23 May 2023
Health Canada’s position on the CADTH guidance for reporting RWE to support decision-making
18 May 2023 - Canada’s CADTH collaborated with Health Canada and other stakeholders to develop the guidance for reporting real world ...
Posted by Michael Wonder on 29 Apr 2023
Prioritising patients in negotiations over drug pricing
14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...
Posted by Michael Wonder on 30 Mar 2023
Clarity around PHARMAC’s priority lists
30 March 2023 - PHARMAC released its first Clarity Report, containing the latest information about medicines, vaccines, and related products ...
Posted by Michael Wonder on 10 Mar 2023
Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices.
10 March 2023 - By law, Medicare will have to take a medication’s efficacy and its research and development costs ...
Posted by Michael Wonder on 05 Mar 2023
Our progress in the funding of medicines for rare disorders
3 March 2023 - PHARMAC will hear from people affected by rare disorders in its upcoming Rare Disorders Advisory Committee meeting ...
Posted by Michael Wonder on 08 Feb 2023
Speeding up access to new medicines in Scotland: abbreviated process
8 February 2023 - A process brought in to streamline decision-making around access to new medicines in NHSScotland during the ...
Posted by Michael Wonder on 04 Feb 2023
NICE’s new methods reflect society’s values
4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...
Posted by Michael Wonder on 07 Jan 2023
Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service
5 January 2023 - The main objective of this study was to explore the extent to which the incremental cost effectiveness ...
Posted by Michael Wonder on 18 Dec 2022
EQ-5D-Y-3L value sets, valuation methods and conceptual questions
12 December 2022 - The measurement and valuation of child health-related quality of life is a rapidly evolving field. ...
Posted by Michael Wonder on 07 Nov 2022
Can we use existing guidance to support the development of robust real world evidence for health technology assessment/payer decision-making?
2 November 2022 - Advances in the digitisation of health systems and expedited regulatory approvals of innovative treatments have led to ...
Posted by Michael Wonder on 22 Oct 2022
Patient centred health technology assessment: a perspective on engagement in health technology assessment by three patient organisations and a health technology assessment body
20 October 2022 - Patient engagement in health technology assessment has become increasingly important over the past 20 years. ...
Posted by Michael Wonder on 14 Sep 2022
Has there actually been early resolution for early resolution resubmissions?
15 September 2022 - Following on from this week's article on early re-entry resubmissions, today we took a close look ...
Posted by Michael Wonder on 08 Sep 2022
Large scale population based surveys linked to administrative health databases as a source of data on health utilities in Australia
8 September 2022 - It is ideal that modelling studies apply health utility values that are compatible, derived using common methods, ...
Posted by Michael Wonder on 08 Sep 2022
Is IQWiG's 15% threshold universally applicable in assessing the clinical relevance of patient reported outcomes changes? An ISPOR Special Interest Group report.
8 September 2022 - To assess the clinical relevance of patient reported outcomes, a response threshold of ≥ 15% of the ...